Over 20 Studies of InnoCare's Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
MWN-AI** Summary
InnoCare Pharma has made a significant impact at the 67th Annual Meeting of the American Society of Hematology (ASH) by presenting over 20 studies featuring its novel BTK inhibitor, orelabrutinib. This compound exhibited impressive efficacy and safety across various lymphoma types, including marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), primary central nervous system lymphoma (PCNSL), and diffuse large B-cell lymphoma (DLBCL).
One highlight from the presentations was a prospective biomarker study in newly diagnosed PCNSL, which showed that mid-treatment cerebrospinal fluid (CSF) ctDNA and MYD88 clearance offered predictive advantages over traditional PET-CT scans regarding treatment response and survival. With an objective response rate (ORR) of 89.5% and a complete response (CR) rate of 78.9%, the combination therapy of orelabrutinib, rituximab, and high-dose methotrexate proved to be effective and well tolerated.
Significant findings also emerged in marginal zone lymphoma, where orelabrutinib combined with obinutuzumab achieved a remarkable ORR of 96% without severe toxicities, and a similar combination with rituximab yielded an ORR of 81.8% in treatment-naïve MZL patients. Furthermore, an innovative regimen combining orelabrutinib with bendamustine-rituximab showed promising outcomes compared to the standard treatment.
Additional studies shed light on the efficacy of orelabrutinib in elderly or frail patients with DLBCL, suggesting favorable outcomes, and real-world data indicated high efficacy in chronic lymphocytic leukemia cases.
InnoCare's presentations at ASH underscore the potential of orelabrutinib as a leading therapeutic option in the oncology landscape, advancing treatment paradigms for challenging hematologic malignancies.
MWN-AI** Analysis
InnoCare Pharma is poised for substantial growth following the recent presentation of over 20 studies regarding its novel BTK inhibitor, orelabrutinib, at the 67th Annual Meeting of the American Society of Hematology (ASH). The findings highlight orelabrutinib's efficacy in treating various lymphomas including marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL).
Key results unveiled indicate a high overall response rate (ORR) and favorable safety profile, positioning orelabrutinib as a potential first-line therapy. For instance, in newly diagnosed primary central nervous system lymphoma (PCNSL), the combination therapy demonstrated an ORR of 89.5% with a 78.9% complete response rate, outpacing traditional PET-CT in predictive capability for treatment response. These groundbreaking findings may catalyze orelabrutinib’s adoption in clinical settings and appeal to investors surveilling advancements in cancer therapeutics.
Notably, the ongoing clinical trials showcase versatility, combining orelabrutinib with other agents such as rituximab and obinutuzumab, which recorded promising ORRs of up to 100% in treatment-naïve MZL patients. This trend suggests that orelabrutinib could become a cornerstone in hematologic oncology, especially given the lack of severe toxicities reported.
From an investment standpoint, InnoCare Pharma's current momentum makes it a compelling opportunity. Its commitment to innovation and the breadth of positive clinical results may enhance its stock attractiveness. The evolving landscape of precision medicine and personal treatment approaches enhances the market potential for orelabrutinib.
Investors should keep a close eye on further clinical data releases and regulatory approvals, as these will be critical indicators of future performance. Establishing positions now could allow investors to benefit from significant price appreciation as InnoCare navigates through this favorable clinical momentum.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 20 studies of its novel BTK inhibitor orelabrutinib were presented at the 67 th Annual Meeting of the American Society of Hematology (ASH).
Orelabrutinib has demonstrated remarkable efficacy and safety in multiple lymphoma studies, including marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), primary central nervous system lymphoma (PCNSL), and diffuse large B-cell lymphoma (DLBCL).
Oral Presentation
Mid-treatment CSF ctdna and MYD88 clearance outperform PET-CT in predicting response and survival to orelabrutinib-based induction in newly diagnosed PCNSL: A prospective biomarker study (Publication No.: 59)
The orelabrutinib, rituximab, and high-dose methotrexate (ORM) induction is effective and well tolerated in newly diagnosed PCNSL. Early cerebrospinal fluid (CSF) ctDNA and MYD88 clearance at mid-treatment offer superior predictive and prognostic value compared to PET-CT. These molecular biomarkers enable real-time risk stratification and may guide early treatment adaptation. Incorporating CSF ctDNA monitoring into clinical workflows has the potential to improve response prediction and long-term outcomes in PCNSL.
Post-cycle 6, objective response rate (ORR) was 89.5%, with 78.9% complete response rate (CR). Median time to response was 2.6 months; 2-year duration of response (DoR) 72.4%. Median follow-up was 18.9 months; estimated 2-year progression-free survival (PFS) and overall survival (OS) were 62.5% and 75.2%, respectively. Treatment was generally well tolerated.
Poster
1. Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study) (Publication No.: 5379)
Orelabrutinib combined with obinutuzumab demonstrated promising antitumor activity in treatment-naïve MZL with no severe toxicities observed. These early results support orelabrutinib combined with obinutuzumab regimen as a potential chemotherapy-free first-line option for MZL.
Among 27 efficacy-evaluable patients: 25 patients completed interim assessment: ORR 96.0%, CR rate 72.0%; 10 patients completed 6 cycles assessment: ORR 100%, CR rate 70.0%.
2. Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial (Publication No.: 3580)
Orelabrutinib combined with rituximab demonstrates promising preliminary efficacy in treatment-naïve MZL patients who failed or were unsuitable for local therapy, with an ORR of 81.8% and a CRR of 72.7%.
Despite current limitations of small sample size and short median follow-up, the orelabrutinib in combination with rituximab regimen represents a promising chemotherapy-free option for these patients.
3. Orelabrutinib plus bendamustine-rituximab (OBR) versus bendamustine-rituximab (BR) in transplant-ineligible, intermediate- to high-risk Mantle Cell Lymphoma (MCL) (Publication No.: 3599)
The orelabrutinib plus bendamustine-rituximab regimen demonstrated a promising tumor response and favorable survival outcomes compared to the bendamustine-rituximab regimen. These findings suggest that the OBR regimen may serve as a promising treatment option for patients with transplant-ineligible, intermediate- to high-risk MCL.
4. Practice pattern and outcomes in DLBCL by Genetic Subtypes: Preliminary results from a large-scale real-world study in China (Publication No.: 3689)
This large-scale real-world study provides treatment patterns and outcomes across DLBCL genetic subtypes in China. Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) plus BTKi demonstrated enhanced efficacy in MCD-like patients, supporting subtype-directed therapy. Updated survival and safety data will be presented.
R-CHOP plus orelabrutinib achieved a CR rate of 81.4% in MCD-like subgroup.
5. Pomalidomide, rituximab, and orelabrutinib in combination with polatuzumab vedotin for newly diagnosed diffuse large B-cell lymphoma in elderly, unfit, or frail patients: a prospective phase II study (Publication No.: 1912)
The preliminary results suggest that the PRO-Pola regimen is a potential treatment option for elderly, unfit, or frail patients with DLBCL, exhibiting promising efficacy and an acceptable safety profile - particularly in those who responded to PRO induction therapy.
Among the patients completed ?3 cycles of treatment, CRR and ORR reached 77.8% and 100.0% respectively. Among the patients who completed all 6 cycles of treatment, both the CRR and ORR reached 100.0%.
Publication Only:
Efficacy and safety of orelabrutinib monotherapy in patients with chronic lymphocytic leukemia: A retrospective real-world study (Abstract ID: abs25-8605)
This real-world study suggested that orelabrutinib monotherapy showed promising efficacy and a favorable safety profile in patients with CLL, both as first-line and subsequent therapy. Patients receiving first-line orelabrutinib achieved both an ORR and DCR of 100%.
More studies on orelabrutinib have been selected for poster presentation and publication only at the 2025 ASH Annual Meeting. The other studies selected for poster presentation are as follows:
- Efficacy and safety of orelabrutinib, obinutuzumab, and lenalidomide in previously untreated marginal zone lymphoma: Preliminary results from a prospective, single-arm, multicenter, Phase II study (Publication No.: 5383)
- Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study (Publication No.: 3596)
- Real-world efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma (Publication No.: 1817)
- Single-cell transcriptomic profiling reveals tumor-intrinsic heterogeneity and immunemicro environment dynamics in the order trial for mantle-cell lymphoma (Publication No.: 1792)
- Orelabrutinib combined with R-CDOP regimen for first-line treatment of diffuse large Bcell lymphoma with high-risk CNS-IPI (Publication No.: 5460)
- Preliminary result of first-line orelabrutinib plus R-CHOP in CD5-positive diffuse large B-cell lymphoma (Rocket trial): A single-arm, phase II trial (Publication No.: 3690)
- Exploration of optimal high-dose methotrexate-based therapy for patients with primary CNS lymphoma: A real-world study in China (Publication No.: 3693)
- Chemotherapy-free induction with pomalidomide, orelabrutinib, and rituximab (POR) followed by high-dose methotrexate,rituximab and orelabrutinin (ROM) in newly diagnosed primary CNS lymphoma: Interim analysis of a phase II study (Publication No.: 5471)
- Orelabrutinib plus anti-PD-1 antibody and fotemustine for newly diagnosed primary central nervous system lymphoma: Phase I/II results (Publication No.: 5465)
- Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma (Publication No.: 1911)
- Primary efficacy and safety of first-line R-MTO regimen (rituximab, methotrexate, thiotepa, and orelabrutinib) followed by autologous hematopoietic stem cell transplantation in PCNSL (Publication No.: 3687)
- Orelabrutinib, sintilimab, and temozolomide (OST) in relapsed/refractory primary central nervous system lymphoma (Publication No.: 5461)
About InnoCare
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.
InnoCare Forward-looking Statements
This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
| Contact | ||
| Media | Investors | |
| Chunhua Lu | ||
| 86-10-66609879 | 86-10-66609999 | |
| chunhua.lu@innocarepharma.com | ir@innocarepharma.com |
FAQ**
How does InnoCare Pharma (INCPF) plan to leverage the promising efficacy of orelabrutinib in various lymphomas to expand its market presence, especially in the face of competitive therapies?
What is InnoCare Pharma's (INCPF) strategy for commercializing orelabrutinib following the successful results from multiple ASH presentations, particularly for treating newly diagnosed primary central nervous system lymphoma?
In light of the findings presented at ASH, how does InnoCare Pharma (INCPF) intend to integrate CSF ctDNA and MYD88 clearance biomarkers into its clinical protocols to enhance patient outcomes for lymphoma treatments?
How might the promising results of orelabrutinib in combination with other agents influence InnoCare Pharma’s (INCPF) future research and development pipeline, particularly for treating marginal zone lymphoma and mantle cell lymphoma?
**MWN-AI FAQ is based on asking OpenAI questions about InnoCare Pharma (OTC: INCPF).
NASDAQ: INCPF
INCPF Trading
0.0% G/L:
$1.55 Last:
1,000 Volume:
$1.55 Open:
